25 XP   0   0   10

Eledon Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Eledon together

PenkeI guess you are interested in Eledon Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Eledon Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Eledon Pharmaceuticals Inc

I send you an email if I find something interesting about Eledon Pharmaceuticals Inc.

Quick analysis of Eledon (30 sec.)










What can you expect buying and holding a share of Eledon? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$3.45
Expected worth in 1 year
$3.41
How sure are you?
27.5%

+ What do you gain per year?

Total Gains per Share
$-0.03
Return On Investment
-1.6%

For what price can you sell your share?

Current Price per Share
$2.06
Expected price per share
$1.42 - $3.7
How sure are you?
50%

1. Valuation of Eledon (5 min.)




Live pricePrice per Share (EOD)

$2.06

Intrinsic Value Per Share

$-11.12 - $-8.21

Total Value Per Share

$-7.68 - $-4.76

2. Growth of Eledon (5 min.)




Is Eledon growing?

Current yearPrevious yearGrowGrow %
How rich?$83.4m$132.7m-$45.3m-51.9%

How much money is Eledon making?

Current yearPrevious yearGrowGrow %
Making money-$9.9m-$21.8m$11.8m118.7%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Eledon (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#408 / 1010

Most Revenue
#993 / 1010

Most Profit
#561 / 1010

Most Efficient
#433 / 1010

What can you expect buying and holding a share of Eledon? (5 min.)

Welcome investor! Eledon's management wants to use your money to grow the business. In return you get a share of Eledon.

What can you expect buying and holding a share of Eledon?

First you should know what it really means to hold a share of Eledon. And how you can make/lose money.

Speculation

The Price per Share of Eledon is $2.06. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Eledon.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Eledon, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.45. Based on the TTM, the Book Value Change Per Share is $-0.01 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.82 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Eledon.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.40-19.3%-0.40-19.2%-0.40-19.6%-0.31-15.1%-0.30-14.4%
Usd Book Value Change Per Share0.4019.3%-0.01-0.4%-0.82-40.0%0.146.9%0.147.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.4019.3%-0.01-0.4%-0.82-40.0%0.146.9%0.147.0%
Usd Price Per Share1.80-1.73-2.86-3.55-4.81-
Price to Earnings Ratio-1.13--1.08--1.76--2.95--4.67-
Price-to-Total Gains Ratio4.52--0.38--7.49--8.19-45.37-
Price to Book Ratio0.52-0.52-0.53-1.36-2.43-
Price-to-Total Gains Ratio4.52--0.38--7.49--8.19-45.37-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.06
Number of shares485
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.010.14
Usd Total Gains Per Share-0.010.14
Gains per Quarter (485 shares)-4.0969.02
Gains per Year (485 shares)-16.35276.09
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-16-260276266
20-33-420552542
30-49-580828818
40-65-74011041094
50-82-90013801370
60-98-106016571646
70-114-122019331922
80-131-138022092198
90-147-154024852474
100-164-170027612750

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.041.00.00.0%
Book Value Change Per Share2.02.00.050.0%2.010.00.016.7%6.014.00.030.0%11.027.02.027.5%11.028.02.026.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.041.00.0%
Total Gains per Share2.02.00.050.0%2.010.00.016.7%6.014.00.030.0%11.027.02.027.5%11.028.02.026.8%

Fundamentals of Eledon

About Eledon Pharmaceuticals Inc

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Fundamental data was last updated by Penke on 2024-04-11 06:46:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Eledon Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Eledon earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Eledon to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Eledon Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-367,772.8%+367,772.8%
5Y-367,772.8%10Y-183,886.4%-183,886.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.2%+207.2%
TTM--216.8%+216.8%
YOY--282.3%+282.3%
5Y-367,772.8%-436.8%-367,336.0%
10Y-183,886.4%-597.3%-183,289.1%
1.1.2. Return on Assets

Shows how efficient Eledon is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Eledon to the Biotechnology industry mean.
  • -7.6% Return on Assets means that Eledon generated $-0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Eledon Pharmaceuticals Inc:

  • The MRQ is -7.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.6%TTM-10.0%+2.4%
TTM-10.0%YOY-20.4%+10.4%
TTM-10.0%5Y-17.3%+7.3%
5Y-17.3%10Y-16.8%-0.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.6%-13.3%+5.7%
TTM-10.0%-12.8%+2.8%
YOY-20.4%-11.6%-8.8%
5Y-17.3%-13.8%-3.5%
10Y-16.8%-15.6%-1.2%
1.1.3. Return on Equity

Shows how efficient Eledon is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Eledon to the Biotechnology industry mean.
  • -11.5% Return on Equity means Eledon generated $-0.12 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Eledon Pharmaceuticals Inc:

  • The MRQ is -11.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -11.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.5%TTM-11.6%+0.1%
TTM-11.6%YOY-22.2%+10.6%
TTM-11.6%5Y-21.2%+9.6%
5Y-21.2%10Y-19.3%-1.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.5%-16.9%+5.4%
TTM-11.6%-16.1%+4.5%
YOY-22.2%-14.9%-7.3%
5Y-21.2%-19.3%-1.9%
10Y-19.3%-20.1%+0.8%

1.2. Operating Efficiency of Eledon Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Eledon is operating .

  • Measures how much profit Eledon makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Eledon to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Eledon Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-391,790.1%+391,790.1%
5Y-391,790.1%10Y-195,895.1%-195,895.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--298.0%+298.0%
TTM--238.5%+238.5%
YOY--288.4%+288.4%
5Y-391,790.1%-486.2%-391,303.9%
10Y-195,895.1%-628.4%-195,266.7%
1.2.2. Operating Ratio

Measures how efficient Eledon is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Eledon Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y3,918.629-3,918.629
5Y3,918.62910Y1,959.314+1,959.314
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.235-3.235
TTM-3.310-3.310
YOY-3.838-3.838
5Y3,918.6295.679+3,912.950
10Y1,959.3147.823+1,951.491

1.3. Liquidity of Eledon Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Eledon is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 14.41 means the company has $14.41 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Eledon Pharmaceuticals Inc:

  • The MRQ is 14.411. The company is very able to pay all its short-term debts. +2
  • The TTM is 15.023. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ14.411TTM15.023-0.612
TTM15.023YOY17.247-2.224
TTM15.0235Y17.216-2.193
5Y17.21610Y14.286+2.930
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.4113.863+10.548
TTM15.0234.169+10.854
YOY17.2475.337+11.910
5Y17.2166.122+11.094
10Y14.2866.434+7.852
1.3.2. Quick Ratio

Measures if Eledon is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Eledon to the Biotechnology industry mean.
  • A Quick Ratio of 25.06 means the company can pay off $25.06 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Eledon Pharmaceuticals Inc:

  • The MRQ is 25.056. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 23.544. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ25.056TTM23.544+1.511
TTM23.544YOY16.658+6.886
TTM23.5445Y18.532+5.012
5Y18.53210Y15.181+3.352
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ25.0563.504+21.552
TTM23.5443.991+19.553
YOY16.6585.371+11.287
5Y18.5326.088+12.444
10Y15.1816.395+8.786

1.4. Solvency of Eledon Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Eledon assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Eledon to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.34 means that Eledon assets are financed with 33.7% credit (debt) and the remaining percentage (100% - 33.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Eledon Pharmaceuticals Inc:

  • The MRQ is 0.337. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.135. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.337TTM0.135+0.202
TTM0.135YOY0.054+0.082
TTM0.1355Y0.1360.000
5Y0.13610Y0.182-0.046
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3370.339-0.002
TTM0.1350.337-0.202
YOY0.0540.271-0.217
5Y0.1360.368-0.232
10Y0.1820.388-0.206
1.4.2. Debt to Equity Ratio

Measures if Eledon is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Eledon to the Biotechnology industry mean.
  • A Debt to Equity ratio of 50.9% means that company has $0.51 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Eledon Pharmaceuticals Inc:

  • The MRQ is 0.509. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.182. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.509TTM0.182+0.327
TTM0.182YOY0.058+0.125
TTM0.1825Y0.509-0.326
5Y0.50910Y0.306+0.203
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5090.392+0.117
TTM0.1820.403-0.221
YOY0.0580.335-0.277
5Y0.5090.427+0.082
10Y0.3060.461-0.155

2. Market Valuation of Eledon Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Eledon generates.

  • Above 15 is considered overpriced but always compare Eledon to the Biotechnology industry mean.
  • A PE ratio of -1.13 means the investor is paying $-1.13 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Eledon Pharmaceuticals Inc:

  • The EOD is -1.295. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.132. Based on the earnings, the company is expensive. -2
  • The TTM is -1.079. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.295MRQ-1.132-0.164
MRQ-1.132TTM-1.079-0.053
TTM-1.079YOY-1.762+0.683
TTM-1.0795Y-2.949+1.871
5Y-2.94910Y-4.668+1.718
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.295-2.300+1.005
MRQ-1.132-2.656+1.524
TTM-1.079-2.718+1.639
YOY-1.762-4.145+2.383
5Y-2.949-6.258+3.309
10Y-4.668-6.315+1.647
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Eledon Pharmaceuticals Inc:

  • The EOD is -1.366. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.193. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.120. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.366MRQ-1.193-0.172
MRQ-1.193TTM-1.120-0.074
TTM-1.120YOY-2.601+1.482
TTM-1.1205Y-3.722+2.602
5Y-3.72210Y-5.142+1.420
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.366-2.974+1.608
MRQ-1.193-3.306+2.113
TTM-1.120-3.508+2.388
YOY-2.601-5.613+3.012
5Y-3.722-8.378+4.656
10Y-5.142-8.873+3.731
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Eledon is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.52 means the investor is paying $0.52 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Eledon Pharmaceuticals Inc:

  • The EOD is 0.598. Based on the equity, the company is cheap. +2
  • The MRQ is 0.522. Based on the equity, the company is cheap. +2
  • The TTM is 0.517. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.598MRQ0.522+0.075
MRQ0.522TTM0.517+0.006
TTM0.517YOY0.533-0.017
TTM0.5175Y1.357-0.841
5Y1.35710Y2.431-1.073
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.5981.914-1.316
MRQ0.5222.116-1.594
TTM0.5172.097-1.580
YOY0.5332.881-2.348
5Y1.3573.550-2.193
10Y2.4313.936-1.505
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Eledon Pharmaceuticals Inc.

3.1. Institutions holding Eledon Pharmaceuticals Inc

Institutions are holding 39.755% of the shares of Eledon Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Bvf Inc17.88030.1598432671000
2023-12-31Armistice Capital, LLC9.04620.0538218900036500020.011
2023-12-31Vanguard Group Inc2.87390695418208983.0982
2023-12-31Woodline Partners LP2.84870.01356893408534714.1305
2023-12-31Ensign Peak Advisors Inc1.83070.001644300100
2023-12-31Geode Capital Management, LLC0.7275017603900
2023-12-31CM Management, LLC0.57860.2025140000-94803-40.3755
2023-12-31Susquehanna International Group, LLP0.35670863232974752.5788
2023-12-31Renaissance Technologies Corp0.28590.000269173720011.618
2023-12-31Ingalls & Snyder LLC0.21430.00425184900
2023-12-31State Street Corporation0.184704469200
2023-12-31Northern Trust Corp0.1649039900-7528-15.8725
2023-12-31BlackRock Inc0.11702830200
2023-12-31Millennium Management LLC0.0945022867-4283-15.7753
2023-12-31Mercer Global Advisors Inc.0.06910.00011672600
2023-12-31Charles Schwab Investment Management Inc0.061901498700
2023-12-31Pathstone Holdings LLC0.05380.000113029130290
2023-09-30Pathstone Family Office, LLC0.05380.000113029130290
2023-12-31TWO SIGMA SECURITIES, LLC0.04870.000211780117800
2023-09-30RMB Capital Management, LLC0.04130.000510000100000
Total 37.53250.43669082165+449416+4.9%

3.2. Funds holding Eledon Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.91140.000172239800
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.92940.000423061684593.8077
2024-02-29Fidelity Extended Market Index0.48390.0006120060-582-0.4824
2024-02-29Vifag 2002 SICAV0.10080.07032500000
2024-02-29Fidelity Series Total Market Index0.08730.00012167400
2023-12-31NT Ext Equity Mkt Idx Fd - L0.0870.000721593-7528-25.8508
2023-12-31Northern Trust Extended Eq Market Idx0.0870.000721593-7528-25.8508
2024-02-29Fidelity Total Market Index0.074401846800
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.06690.00051660900
2024-02-29Schwab Total Stock Market Index0.06040.00011498700
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.05380.000513339250.1878
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.05350.000113263-446735-97.1167
2024-02-29Vanguard Instl Ttl Stk Mkt Idx InstlPls0.05350.00011326300
2024-02-29Fidelity Nasdaq Composite Index0.04220.00011048200
2023-12-31SSgA U.S. Extended Market Index Class I0.02540.0004630000
2024-03-31State St US Extended Mkt Indx NL Cl C0.02540.0007630000
2024-02-29Spartan Total Market Index Pool E0.02160534900
2024-02-29Spartan Extended Market Index Pool E0.01890.0003469458214.1537
2023-12-31SSgA U.S. Total Market Index Strategy0.00730.00011817-42-2.2593
2024-02-29State St US Ttl Mkt Indx SL Cl I0.00640160000
Total 5.19650.07581289405-453349-35.2%

3.3. Insider Transactions

Insiders are holding 5.563% of the shares of Eledon Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2021-12-20David-alexandre C GrosBUY20004.48
2021-08-17David-alexandre C GrosBUY40006.21
2021-06-09David-alexandre C. GrosBUY30008.01

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Eledon Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.398-0.008+102%-0.825+307%0.142+180%0.143+178%
Book Value Per Share--3.4453.428+0%5.486-37%3.806-9%2.714+27%
Current Ratio--14.41115.023-4%17.247-16%17.216-16%14.286+1%
Debt To Asset Ratio--0.3370.135+149%0.054+527%0.136+148%0.182+86%
Debt To Equity Ratio--0.5090.182+179%0.058+784%0.509+0%0.306+66%
Dividend Per Share----0%-0%-0%-0%
Eps---0.398-0.3960%-0.405+2%-0.312-22%-0.296-26%
Free Cash Flow Per Share---0.377-0.384+2%-0.294-22%-0.255-32%-0.259-31%
Free Cash Flow To Equity Per Share---0.3770.298-226%0.389-197%0.458-182%0.206-283%
Gross Profit Margin--1.0101.002+1%1.000+1%1.000+1%1.102-8%
Intrinsic Value_10Y_max---8.206--------
Intrinsic Value_10Y_min---11.122--------
Intrinsic Value_1Y_max---1.005--------
Intrinsic Value_1Y_min---1.278--------
Intrinsic Value_3Y_max---2.880--------
Intrinsic Value_3Y_min---3.721--------
Intrinsic Value_5Y_max---4.587--------
Intrinsic Value_5Y_min---6.015--------
Market Cap49848086.000+13%43583634.00043726868.7500%69085575.500-37%86237369.190-49%116586536.005-63%
Net Profit Margin----0%-0%-3677.7280%-1838.8640%
Operating Margin----0%-0%-3917.9010%-1958.9510%
Operating Ratio----0%-0%3918.629-100%1959.314-100%
Pb Ratio0.598+13%0.5220.517+1%0.533-2%1.357-62%2.431-79%
Pe Ratio-1.295-14%-1.132-1.079-5%-1.762+56%-2.949+161%-4.668+312%
Price Per Share2.060+13%1.8001.725+4%2.855-37%3.547-49%4.810-63%
Price To Free Cash Flow Ratio-1.366-14%-1.193-1.120-6%-2.601+118%-3.722+212%-5.142+331%
Price To Total Gains Ratio5.175+13%4.522-0.377+108%-7.489+266%-8.186+281%45.373-90%
Quick Ratio--25.05623.544+6%16.658+50%18.532+35%15.181+65%
Return On Assets---0.076-0.100+31%-0.204+167%-0.173+127%-0.168+120%
Return On Equity---0.115-0.116+1%-0.222+92%-0.212+84%-0.193+68%
Total Gains Per Share--0.398-0.008+102%-0.825+307%0.142+180%0.143+178%
Usd Book Value--83419000.00087373750.000-5%132743250.000-37%92979900.000-10%66112650.000+26%
Usd Book Value Change Per Share--0.398-0.008+102%-0.825+307%0.142+180%0.143+178%
Usd Book Value Per Share--3.4453.428+0%5.486-37%3.806-9%2.714+27%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.398-0.3960%-0.405+2%-0.312-22%-0.296-26%
Usd Free Cash Flow---9131000.000-9881750.000+8%-7106000.000-22%-6296650.000-31%-6314775.000-31%
Usd Free Cash Flow Per Share---0.377-0.384+2%-0.294-22%-0.255-32%-0.259-31%
Usd Free Cash Flow To Equity Per Share---0.3770.298-226%0.389-197%0.458-182%0.206-283%
Usd Market Cap49848086.000+13%43583634.00043726868.7500%69085575.500-37%86237369.190-49%116586536.005-63%
Usd Price Per Share2.060+13%1.8001.725+4%2.855-37%3.547-49%4.810-63%
Usd Profit---9626000.000-9997000.000+4%-21868250.000+127%-10039450.000+4%-8402700.000-13%
Usd Revenue----0%-0%18006.000-100%9003.000-100%
Usd Total Gains Per Share--0.398-0.008+102%-0.825+307%0.142+180%0.143+178%
 EOD+6 -2MRQTTM+18 -12YOY+14 -165Y+13 -1910Y+14 -18

4.2. Fundamental Score

Let's check the fundamental score of Eledon Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.295
Price to Book Ratio (EOD)Between0-10.598
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than125.056
Current Ratio (MRQ)Greater than114.411
Debt to Asset Ratio (MRQ)Less than10.337
Debt to Equity Ratio (MRQ)Less than10.509
Return on Equity (MRQ)Greater than0.15-0.115
Return on Assets (MRQ)Greater than0.05-0.076
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Eledon Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.583
Ma 20Greater thanMa 501.820
Ma 50Greater thanMa 1001.802
Ma 100Greater thanMa 2001.734
OpenGreater thanClose2.050
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets125,894
Total Liabilities42,475
Total Stockholder Equity83,419
 As reported
Total Liabilities 42,475
Total Stockholder Equity+ 83,419
Total Assets = 125,894

Assets

Total Assets125,894
Total Current Assets56,129
Long-term Assets69,765
Total Current Assets
Cash And Cash Equivalents 4,612
Short-term Investments 46,490
Other Current Assets 5,027
Total Current Assets  (as reported)56,129
Total Current Assets  (calculated)56,129
+/-0
Long-term Assets
Property Plant Equipment 365
Intangible Assets 32,386
Long-term Assets Other 186
Long-term Assets  (as reported)69,765
Long-term Assets  (calculated)32,937
+/- 36,828

Liabilities & Shareholders' Equity

Total Current Liabilities3,895
Long-term Liabilities38,580
Total Stockholder Equity83,419
Total Current Liabilities
Short-term Debt 383
Accounts payable 967
Other Current Liabilities 2,545
Total Current Liabilities  (as reported)3,895
Total Current Liabilities  (calculated)3,895
+/-0
Long-term Liabilities
Capital Lease Obligations 383
Long-term Liabilities  (as reported)38,580
Long-term Liabilities  (calculated)383
+/- 38,197
Total Stockholder Equity
Common Stock24
Retained Earnings -243,191
Other Stockholders Equity 326,586
Total Stockholder Equity (as reported)83,419
Total Stockholder Equity (calculated)83,419
+/-0
Other
Capital Stock24
Cash and Short Term Investments 51,102
Common Stock Shares Outstanding 24,213
Liabilities and Stockholders Equity 125,894
Net Debt -4,229
Net Invested Capital 83,419
Net Working Capital 52,234
Property Plant and Equipment Gross 365
Short Long Term Debt Total 383



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-30
> Total Assets 
0
32,287
0
23,420
106,983
107,744
96,650
87,410
77,607
67,974
57,710
46,857
36,721
29,761
25,831
26,844
23,019
20,892
20,892
22,965
19,928
17,026
13,451
18,216
15,218
10,931
13,720
10,501
192,585
197,185
191,682
184,305
177,170
170,548
161,378
154,706
149,586
92,793
82,306
106,785
96,069
125,894
125,89496,069106,78582,30692,793149,586154,706161,378170,548177,170184,305191,682197,185192,58510,50113,72010,93115,21818,21613,45117,02619,92822,96520,89220,89223,01926,84425,83129,76136,72146,85757,71067,97477,60787,41096,650107,744106,98323,420032,2870
   > Total Current Assets 
0
32,178
0
21,739
106,724
107,511
96,332
86,756
76,865
67,170
56,987
46,186
36,334
29,543
25,631
24,843
21,035
19,000
19,000
21,078
17,110
14,276
10,321
15,181
12,296
9,971
12,873
9,761
115,101
115,630
110,241
102,582
95,558
88,346
79,325
72,788
67,565
59,518
48,904
73,622
62,991
56,129
56,12962,99173,62248,90459,51867,56572,78879,32588,34695,558102,582110,241115,630115,1019,76112,8739,97112,29615,18110,32114,27617,11021,07819,00019,00021,03524,84325,63129,54336,33446,18656,98767,17076,86586,75696,332107,511106,72421,739032,1780
       Cash And Cash Equivalents 
0
31,753
0
21,150
105,464
105,256
94,162
59,084
33,168
24,023
14,303
12,156
18,630
23,223
24,400
22,498
19,094
17,233
17,233
19,189
16,324
12,972
9,056
13,703
10,814
8,791
11,785
8,764
114,464
114,195
108,579
101,133
94,041
84,833
76,677
70,460
65,889
56,409
46,485
40,947
3,667
4,612
4,6123,66740,94746,48556,40965,88970,46076,67784,83394,041101,133108,579114,195114,4648,76411,7858,79110,81413,7039,05612,97216,32419,18917,23317,23319,09422,49824,40023,22318,63012,15614,30324,02333,16859,08494,162105,256105,46421,150031,7530
       Short-term Investments 
0
0
0
0
0
0
0
24,110
39,935
39,934
39,947
31,771
16,088
4,175
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,431
55,942
46,490
46,49055,94230,43100000000000000000000000004,17516,08831,77139,94739,93439,93524,1100000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
747
739
956
245
247
162
214
110
197
87
0
0
0
0
0
0
0
0
0
0
0000000000871971102141622472459567397470000000000000000000000
       Other Current Assets 
0
425
0
589
1,260
2,255
2,170
3,562
3,762
3,213
2,737
2,259
1,616
2,145
1,231
2,345
1,941
0
18
15
15
630
27
78
15
54
64
83
17
38
1,662
11
11
34
17
32
57
28
47
238
90
5,027
5,0279023847285732173411111,662381783645415782763015151801,9412,3451,2312,1451,6162,2592,7373,2133,7623,5622,1702,2551,26058904250
   > Long-term Assets 
0
109
0
1,681
259
233
318
654
742
804
723
671
387
218
200
2,001
1,984
1,892
1,892
1,887
2,818
2,750
3,130
3,035
2,922
960
847
740
77,484
81,555
81,441
81,723
81,612
82,202
82,053
81,918
82,021
33,275
33,402
33,163
33,078
69,765
69,76533,07833,16333,40233,27582,02181,91882,05382,20281,61281,72381,44181,55577,4847408479602,9223,0353,1302,7502,8181,8871,8921,8921,9842,0012002183876717238047426543182332591,68101090
       Property Plant Equipment 
0
29
0
36
38
33
73
339
427
489
453
401
117
98
80
49
47
25
25
20
17
14
458
413
367
321
275
229
183
138
92
267
222
768
675
581
832
739
647
553
459
365
36545955364773983258167576822226792138183229275321367413458141720252547498098117401453489427339733338360290
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,867
1,867
1,867
1,867
1,867
1,867
1,867
1,867
1,867
1,867
0
0
0
44,466
48,648
48,648
48,648
48,648
48,648
48,648
48,648
48,648
0
0
0
0
0
0000048,64848,64848,64848,64848,64848,64848,64848,64844,4660001,8671,8671,8671,8671,8671,8671,8671,8671,8671,867000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,38632,38632,38632,38632,38632,38632,38632,38632,38632,38632,38632,38632,38632,3860000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
639
572
511
33,018
32,907
315
422
356
400
344
303
155
0
0
224
0
0
002240015530334440035642231532,90733,0185115726390000000000000000000000000
> Total Liabilities 
0
87,554
0
3,688
5,372
4,243
5,754
4,660
5,708
6,250
6,303
7,973
6,464
2,903
2,467
3,405
2,400
1,440
1,440
1,452
1,603
2,534
3,522
2,184
1,852
1,466
1,975
1,145
171,079
6,589
7,811
5,784
6,422
6,553
5,060
5,327
8,493
8,610
7,514
6,836
4,734
42,475
42,4754,7346,8367,5148,6108,4935,3275,0606,5536,4225,7847,8116,589171,0791,1451,9751,4661,8522,1843,5222,5341,6031,4521,4401,4402,4003,4052,4672,9036,4647,9736,3036,2505,7084,6605,7544,2435,3723,688087,5540
   > Total Current Liabilities 
0
2,209
0
3,688
5,372
4,243
5,754
4,647
5,657
6,162
6,177
7,817
6,344
2,819
2,419
3,160
2,306
1,440
1,440
1,452
1,603
2,534
3,241
1,948
1,661
1,322
1,878
1,097
6,130
2,483
4,206
2,677
4,046
4,401
2,958
3,276
6,280
6,475
5,478
4,900
2,899
3,895
3,8952,8994,9005,4786,4756,2803,2762,9584,4014,0462,6774,2062,4836,1301,0971,8781,3221,6611,9483,2412,5341,6031,4521,4401,4402,3063,1602,4192,8196,3447,8176,1776,1625,6574,6475,7544,2435,3723,68802,2090
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
170
173
177
180
184
188
191
144
97
179
177
369
328
287
378
363
384
390
396
383
383396390384363378287328369177179971441911881841801771731700000000000000000000000
       Accounts payable 
0
5
0
1,216
2,889
765
3,434
1,704
1,652
1,208
1,886
1,846
886
430
276
374
189
0
418
706
751
689
480
753
256
329
741
150
758
1,366
1,514
857
1,598
1,813
1,026
1,318
3,859
2,200
2,852
2,197
465
967
9674652,1972,8522,2003,8591,3181,0261,8131,5988571,5141,36675815074132925675348068975170641801893742764308861,8461,8861,2081,6521,7043,4347652,8891,216050
       Other Current Liabilities 
0
2,204
0
2,472
2,483
3,478
2,320
2,943
4,005
4,954
4,291
5,971
5,458
2,389
2,143
2,786
2,117
0
1,022
746
852
1,845
170
1,022
1,228
813
953
759
5,181
973
2,595
1,641
2,271
2,219
1,604
1,671
2,043
3,912
2,242
2,313
2,038
2,545
2,5452,0382,3132,2423,9122,0431,6711,6042,2192,2711,6412,5959735,1817599538131,2281,0221701,8458527461,02202,1172,7862,1432,3895,4585,9714,2914,9544,0052,9432,3203,4782,4832,47202,2040
   > Long-term Liabilities 
0
85,345
0
0
0
0
0
13
51
88
126
156
120
84
48
245
94
0
1,022
746
852
1,845
281
236
191
144
97
48
164,949
4,106
3,605
3,107
2,376
2,152
2,102
2,051
2,213
2,135
2,036
1,936
1,835
38,580
38,5801,8351,9362,0362,1352,2132,0512,1022,1522,3763,1073,6054,106164,94948971441912362811,8458527461,02209424548841201561268851130000085,3450
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,106
3,605
3,017
2,331
1,752
1,752
1,752
1,752
0
0
1,752
0
0
001,752001,7521,7521,7521,7522,3313,0173,6054,10600000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,752
0
0
0
0001,75200000000000000000000000000000000000000
> Total Stockholder Equity
0
-55,267
0
19,732
101,611
103,501
90,896
82,750
71,899
61,724
51,407
38,884
30,257
26,858
23,364
23,439
20,619
0
19,452
21,513
18,325
14,492
9,929
16,032
13,366
9,465
11,745
9,356
21,506
190,596
183,871
178,521
170,748
163,995
156,318
149,379
141,093
84,183
74,792
99,949
91,335
83,419
83,41991,33599,94974,79284,183141,093149,379156,318163,995170,748178,521183,871190,59621,5069,35611,7459,46513,36616,0329,92914,49218,32521,51319,452020,61923,43923,36426,85830,25738,88451,40761,72471,89982,75090,896103,501101,61119,7320-55,2670
   Common Stock
0
0
0
15
22
22
22
22
23
23
23
23
23
23
23
7
7
0
7
9
9
9
9
13
13
13
16
19
1
15
14
14
14
14
14
14
14
14
14
23
24
24
242423141414141414141414151191613131399997077232323232323232222222215000
   Retained Earnings Total Equity000-213,63700000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
-43
0
0
-106,983
-58
0
-2
8
-55
-5
6
3
-1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-90,460
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000-90,46000000000000000-136-5-558-20-58-106,98300-430
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
288,415
0
0
0
000288,41500000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
7,831
0
93,470
181,732
82,144
190,485
191,298
192,289
193,194
194,253
195,245
195,891
196,233
196,604
45,858
46,008
0
46,951
55,005
55,313
56,054
56,372
66,564
66,791
67,034
77,488
77,682
21,505
270,974
272,749
274,783
276,827
278,880
281,067
283,375
285,560
287,034
288,415
323,142
324,876
326,586
326,586324,876323,142288,415287,034285,560283,375281,067278,880276,827274,783272,749270,97421,50577,68277,48867,03466,79166,56456,37256,05455,31355,00546,951046,00845,858196,604196,233195,891195,245194,253193,194192,289191,298190,48582,144181,73293,47007,8310



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-374
Gross Profit-374-374
 
Operating Income (+$)
Gross Profit-374
Operating Expense-42,626
Operating Income-43,000-43,000
 
Operating Expense (+$)
Research Development30,312
Selling General Administrative12,207
Selling And Marketing Expenses0
Operating Expense42,62642,519
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-43,000
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-40,326-45,674
EBIT - interestExpense = -43,000
-40,326
-40,326
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-43,000-40,326
Earnings Before Interest and Taxes (EBITDA)-42,626
 
After tax Income (+$)
Income Before Tax-40,326
Tax Provision-0
Net Income From Continuing Ops-89,084-40,326
Net Income-40,326
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses43,000
Total Other Income/Expenses Net2,6740
 

Technical Analysis of Eledon
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Eledon. The general trend of Eledon is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Eledon's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Eledon Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2.23 < 2.95 < 3.7.

The bearish price targets are: 1.52 > 1.5199 > 1.42.

Tweet this
Eledon Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Eledon Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Eledon Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Eledon Pharmaceuticals Inc. The current macd is 0.06406155.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Eledon price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Eledon. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Eledon price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Eledon Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartEledon Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Eledon Pharmaceuticals Inc. The current adx is 24.18.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Eledon shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Eledon Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Eledon Pharmaceuticals Inc. The current sar is 1.69251318.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Eledon Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Eledon Pharmaceuticals Inc. The current rsi is 58.58. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Eledon Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartEledon Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Eledon Pharmaceuticals Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Eledon price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Eledon Pharmaceuticals Inc Daily Stochastic Oscillator ChartEledon Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Eledon Pharmaceuticals Inc. The current cci is 95.30.

Eledon Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartEledon Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Eledon Pharmaceuticals Inc. The current cmo is 21.21.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Eledon Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartEledon Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Eledon Pharmaceuticals Inc. The current willr is -20.58823529.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Eledon is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Eledon Pharmaceuticals Inc Daily Williams %R ChartEledon Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Eledon Pharmaceuticals Inc. The current atr is 0.19425352.

Eledon Pharmaceuticals Inc Daily Average True Range (ATR) ChartEledon Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Eledon Pharmaceuticals Inc. The current obv is 4,361,609.

Eledon Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartEledon Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Eledon Pharmaceuticals Inc. The current mfi is 80.03.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Eledon Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartEledon Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Eledon Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-13WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-15BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-03MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-17MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-26STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside

6.3. Candlestick Patterns

Eledon Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Eledon Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.583
Ma 20Greater thanMa 501.820
Ma 50Greater thanMa 1001.802
Ma 100Greater thanMa 2001.734
OpenGreater thanClose2.050
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Eledon with someone you think should read this too:
  • Are you bullish or bearish on Eledon? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Eledon? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Eledon Pharmaceuticals Inc

I send you an email if I find something interesting about Eledon Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Eledon Pharmaceuticals Inc.

Receive notifications about Eledon Pharmaceuticals Inc in your mailbox!